{"schema_version":"secwatch.filing_event.v1","accession":"0001531048-24-000034","form_type":"8-K","ticker":null,"cik":"0001531048","company_name":"Inari Medical, Inc.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.868359+00:00","generated_at":"2026-06-03T04:21:25.686834+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Inari Medical Q1 revenue $143.2M (+23% YoY); raises FY2024 guidance, GAAP net loss widens to $24.2M","bullets":["Revenue $143.2M, up 23.3% YoY; gross margin 86.8% (down from 88.2% prior year).","GAAP operating loss $17.2M vs $5.3M loss in Q1 2023; net loss $24.2M ($0.42 loss per share).","Non-GAAP operating loss $5.6M, excluding $6.3M contingent consideration, $2.8M acquisition costs, $2.5M amortization.","Raises FY2024 revenue guidance to $592.5M-$602.5M (from $580M-$595M); expects sustained profitability in H1 2025.","PEERLESS study on track for H2 2024; growth driven by commercial expansion and new products."],"urls":{"canonical":"https://secwatch.observer/filing/0001531048-24-000034","json":"https://secwatch.observer/filing/0001531048-24-000034.json","markdown":"https://secwatch.observer/filing/0001531048-24-000034.md","text":"https://secwatch.observer/filing/0001531048-24-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531048/000153104824000034/0001531048-24-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531048/000153104824000034/nari-20240430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:21:25.686834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bbc0a30e32bd5522ad1f934d573438dae516b5f6","claim":"Inari Medical, Inc. reported first quarter ended March 31, 2024 results: revenue $143.2 million, net income Net loss was $24.2 million, EPS net loss per share was $0.42. Guidance raised.","evidence_excerpt":"and other diseases, today reported financial results for its first quarter ended March 31, 2024. First Quarter Financial and Recent Business Highlights • Generated revenue of $143.2 million in Q1 of 2024, up 23.3% over the same quarter last year. • GAAP operating loss was $17.2 million in Q1 of 2024, compared to a $5.3 million operating loss in the same quarter of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1531048/000153104824000034/0001531048-24-000034-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$143.2 million"},{"label":"Net income","value":"Net loss was $24.2 million"},{"label":"EPS","value":"net loss per share was $0.42"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}